BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI

BRISTOL MYERS SQUIBB CO

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$58.83−0.92 (-1.54%)

Close on Oct 19, 2026

Community

Notes and questions about Bristol Myers Squibb from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Bristol Myers Squibb's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Mar 1, 1999
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BMY.

Revenue growth3.1% · median 9.7%

Gross margin70.2% · median 71.5%

Net margin18.9% · median 9.8%

Advertisement
300 × 250